Frederick W K Tam

List of Publications by Year
in descending order

92 papers	3,893 citations	109321 35 h-index	128289 60 g-index
93 all docs	93 docs citations	93 times ranked	4933 citing authors

#	Article	IF	Citations
1	Inhibition of spleen tyrosine kinase decreases donor specific antibody levels in a rat model of sensitization. Scientific Reports, 2022, 12, 3330.	3.3	5
2	Impact of kidney size on the outcome of diabetic patients receiving hemodialysis. PLoS ONE, 2022, 17, e0266231.	2.5	2
3	Glomerulonephritis and autoimmune vasculitis are independent of <scp>P2RX7</scp> but may depend on alternative inflammasome pathways. Journal of Pathology, 2022, 257, 300-313.	4.5	3
4	Impact of kidney size on mortality in diabetic patients receiving peritoneal dialysis. Scientific Reports, 2021, 11, 8203.	3.3	4
5	Masked crystalline light chain tubulopathy and podocytopathy with focal segmental glomerulosclerosis: a rare MGRSâ€associated renal lesion. Histopathology, 2021, 79, 265-268.	2.9	1
6	Characterisation of an enhanced preclinical model of experimental MPOâ€ANCA autoimmune vasculitis. Journal of Pathology, 2021, 255, 107-119.	4.5	4
7	Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis. Kidney International, 2021, 100, 1316-1324.	5.2	26
8	Renal monocyte chemoattractant protein-1: an emerging universal biomarker and therapeutic target for kidney diseases?. Nephrology Dialysis Transplantation, 2020, 35, 198-203.	0.7	12
9	A High-Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury. Cell Reports Medicine, 2020, 1, 100137.	6.5	56
10	Global microRNA profiling in human urinary exosomes reveals novel disease biomarkers and cellular pathways for autosomal dominant polycystic kidney disease. Kidney International, 2020, 98, 420-435.	5.2	40
11	Spleen tyrosine kinase inhibition is an effectiveÂtreatment for established vasculitis inÂaÂpre-clinical model. Kidney International, 2020, 97, 1196-1207.	5.2	34
12	Higher serum galactose-deficient immunoglobulin A1 concentration is associated with stronger mesangial cellular inflammatory response and more severe histologic findings in immunoglobulin A nephropathy. CKJ: Clinical Kidney Journal, 2019, 12, 232-238.	2.9	14
13	211.â€ƒA NOVEL P2X7 KNOCKOUT RAT IS NOT PROTECTED FROM EXPERIMENTAL GLOMERULONEPHRITIS OR VASCULITIS. Rheumatology, 2019, 58, .	1.9	0
14	214.â€ƒTHE EFFECT OF P2X7 ANTAGONISM ON NEPHROTOXIC NEPHRITIS. Rheumatology, 2019, 58, .	1.9	0
15	Autologous Stem Cell Transplant for the Treatment of Type I Crystal Cryoglobulinemic Glomerulonephritis Caused by Monoclonal Gammopathy of Renal Significance (MGRS). Kidney International Reports, 2019, 4, 1342-1348.	0.8	6
16	Plasmacytoma-Like Posttransplant Lymphoproliferative Disease in a Disused Arteriovenous Fistula: The Importance ofÂHistopathology. Kidney International Reports, 2019, 4, 749-755.	0.8	1
17	Dr. Kang, et al, reply. Journal of Rheumatology, 2019, 46, 1244.2-1244.	2.0	0
18	Dr. Kang, et al reply. Journal of Rheumatology, 2019, 46, 866.2-867.	2.0	0

#	Article	IF	Citations
19	Modification of an aggressive model of Alport Syndrome reveals early differences in disease pathogenesis due to genetic background. Scientific Reports, 2019, 9, 20398.	3.3	11
20	P2X7 Receptor Stimulation Is Not Required for Oxalate Crystal-Induced Kidney Injury. Scientific Reports, 2019, 9, 20086.	3.3	7
21	High Incidence of Arterial and Venous Thrombosis in Antineutrophil Cytoplasmic Antibodyâ€“associated Vasculitis. Journal of Rheumatology, 2019, 46, 285-293.	2.0	38
22	P2X₇ receptor antagonism ameliorates renal dysfunction in a rat model of sepsis. Physiological Reports, 2018, 6, e13622.	1.7	19
23	Defining Phenotypes in Diabetic Nephropathy: a novel approach using a cross-sectional analysis of a single centre cohort. Scientific Reports, 2018, 8, 53.	3.3	9
24	Renal Tubular Cell Mitochondrial Dysfunction Occurs Despite Preserved Renal Oxygen Delivery in Experimental Septic Acute Kidney Injury. Critical Care Medicine, 2018, 46, e318-e325.	0.9	36
25	TESTING Corticosteroids in IgA Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 158-160.	4.5	16
26	Role of the Spleen Tyrosine Kinase Pathway in Driving Inflammation in IgA Nephropathy. Seminars in Nephrology, 2018, 38, 496-503.	1.6	19
27	Primary IgA nephropathy: current challenges and future prospects. International Journal of Nephrology and Renovascular Disease, 2018, Volume 11, 137-148.	1.8	32
28	Alkylating histone deacetylase inhibitors may have therapeutic value in experimental myeloperoxidase-ANCA vasculitis. Kidney International, 2018, 94, 926-936.	5.2	3
29	Long-term outcome in biopsy-proven acute interstitial nephritis treated with steroids. CKJ: Clinical Kidney Journal, 2017, 10, sfw116.	2.9	37
30	Hyperglycemia-induced Renal P2X7 Receptor Activation Enhances Diabetes-related Injury. EBioMedicine, 2017, 19, 73-83.	6.1	64
31	Label Free Detection of Sensitive Mid-Infrared Biomarkers of Glomerulonephritis in Urine Using Fourier Transform Infrared Spectroscopy. Scientific Reports, 2017, 7, 4601.	3.3	38
32	CCL18 synergises with high concentrations of glucose in stimulating fibronectin production in human renal tubuloepithelial cells. BMC Nephrology, 2016, 17, 139.	1.8	5
33	Is P2X7 a potential therapeutic target in the treatment of retinal diseases: an animal study. Lancet, The, 2016, 387, S91.	13.7	0
34	Selective Targeting of a Disease-Related Conformational Isoform of Macrophage Migration Inhibitory Factor Ameliorates Inflammatory Conditions. Journal of Immunology, 2015, 195, 2343-2352.	0.8	37
35	Correlation of disease activity in proliferative glomerulonephritis with glomerular spleen tyrosine kinase expression. Kidney International, 2015, 88, 52-60.	5.2	34
36	Inhibition of the purinergic P2X7 receptor improves renal perfusion in angiotensin-II-infused rats. Kidney International, 2015, 88, 1079-1087.	5.2	48

#	Article	IF	Citations
37	Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the international histological classification and other prognostic factors. Nephrology Dialysis Transplantation, 2015, 30, 1185-1192.	0.7	94
38	Dialysate Cytokine Levels do not Predict Encapsulating Peritoneal Sclerosis. Peritoneal Dialysis International, 2014, 34, 594-604.	2.3	23
39	Spleen Tyrosine Kinase Inhibition Attenuates Autoantibody Production and Reverses Experimental Autoimmune GN. Journal of the American Society of Nephrology: JASN, 2014, 25, 2291-2302.	6.1	46
40	Exaggerated renal fibrosis in P2X4 receptor-deficient mice following unilateral ureteric obstruction. Nephrology Dialysis Transplantation, 2014, 29, 1350-1361.	0.7	24
41	SYK inhibition in experimental autoimmune vasculitis and its glomerular expression in ANCA-associated vasculitis. Lancet, The, 2014, 383, S72.	13.7	5
42	Effect of bariatric surgery-induced weight loss on renal and systemic inflammation and blood pressure: a 12-month prospective study. Surgery for Obesity and Related Diseases, 2013, 9, 559-568.	1.2	117
43	P2X7 receptor-mediated Nlrp3-inflammasome activation is a genetic determinant of macrophage-dependent crescentic glomerulonephritis. Journal of Leukocyte Biology, 2013, 93, 127-134.	3.3	50
44	B-cell-targeted therapy in adult glomerulonephritis. Expert Opinion on Biological Therapy, 2013, 13, 1691-1706.	3.1	11
45	The effect of bariatric surgery on renal function and disease: a focus on outcomes and inflammation. Nephrology Dialysis Transplantation, 2013, 28, iv73-iv82.	0.7	33
46	Currently available and potential future treatment options for IgA nephropathy. Expert Opinion on Orphan Drugs, 2013, 1, 625-635.	0.8	0
47	Purinergic signaling in inflammatory renal disease. Frontiers in Physiology, 2013, 4, 194.	2.8	24
48	<scp>ATP</scp> and arterial calcification. European Journal of Clinical Investigation, 2013, 43, 405-412.	3.4	18
49	Interdependent expression of P2X receptors in the mouse kidney: P2X4â€P2X7 receptor â€œcrossâ€talkâ€. FASEB Journal, 2013, 27, 884.3.	0.5	1
50	Spleen Tyrosine Kinase Is Important in the Production of Proinflammatory Cytokines and Cell Proliferation in Human Mesangial Cells following Stimulation with IgA1 Isolated from IgA Nephropathy Patients. Journal of Immunology, 2012, 189, 3751-3758.	0.8	65
51	P2 purinoceptors: Renal pathophysiology and therapeutic potential. Clinical Nephrology, 2012, 78, 154-163.	0.7	31
52	A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases. Expert Opinion on Investigational Drugs, 2011, 20, 897-915.	4.1	212
53	Sodium and water handling after gastric bypass surgery in a rat model. Surgery for Obesity and Related Diseases, 2011, 7, 68-73.	1.2	25
54	Oral cholecalciferol decreases albuminuria and urinary TGF-Î²1 in patients with type 2 diabetic nephropathy on established reninâ€“angiotensinâ€“aldosterone system inhibition. Kidney International, 2011, 80, 851-860.	5.2	110

#	Article	IF	Citations
55	Urinary monocyte chemoattractant protein-1 in renal disease. Clinica Chimica Acta, 2011, 412, 2022-2030.	1.1	83
56	Urine Proteomics and Biomarkers in Renal Disease. Nephron Experimental Nephrology, 2011, 119, e1-e7.	2.2	15
57	Fostamatinib disodium. Drugs of the Future, 2011, 36, 273.	0.1	40
58	Effect of IL-11 on glomerular expression of TGF-beta and extracellular matrix in nephrotoxic nephritis in Wistar Kyoto rats. Journal of Nephrology, 2011, 24, 106-111.	2.0	11
59	CCL18 in peritoneal dialysis patients and encapsulating peritoneal sclerosis. European Journal of Clinical Investigation, 2010, 40, 1067-1073.	3.4	21
60	A Spleen Tyrosine Kinase Inhibitor Reduces the Severity of Established Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2010, 21, 231-236.	6.1	74
61	Genetic Loci Modulate Macrophage Activity and Glomerular Damage in Experimental Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2010, 21, 1136-1144.	6.1	23
62	Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica, 2010, 95, 505-508.	3.5	159
63	Renal cytokines and biochemical profiles after bariatric surgery. Surgery for Obesity and Related Diseases, 2010, 6, 228-229.	1.2	0
64	Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney International, 2009, 75, 976-981.	5.2	266
65	Sustained appetite improvement in malnourished dialysis patients by daily ghrelin treatment. Kidney International, 2009, 76, 199-206.	5.2	118
66	P2X7 Deficiency Attenuates Renal Injury in Experimental Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2009, 20, 1275-1281.	6.1	105
67	Lymphocytes from P2X7-deficient mice exhibit enhanced P2X7responses. Journal of Leukocyte Biology, 2009, 85, 978-986.	3.3	43
68	P2 receptors in renal pathophysiology. Purinergic Signalling, 2009, 5, 513-520.	2.2	17
69	Urinary monocyte chemoattractant protein-1 (MCP-1) and connective tissue growth factor (CCN2) as prognostic markers for progression of diabetic nephropathy. Cytokine, 2009, 47, 37-42.	3.2	99
70	Assessing Glycemic Control in Maintenance Hemodialysis Patients With Type 2 Diabetes. Diabetes Care, 2009, 32, 1137-1142.	8.6	104
71	Genes Expressed by Both Mesangial Cells and Bone Marrowâ€“Derived Cells Underlie Genetic Susceptibility to Crescentic Glomerulonephritis in the Rat. Journal of the American Society of Nephrology: JASN, 2007, 18, 1816-1823.	6.1	20
72	Inhibition of p38 Mitogen-Activated Protein Kinase Is Effective in the Treatment of Experimental Crescentic Glomerulonephritis and Suppresses Monocyte Chemoattractant Protein-1 but Not IL-1Î² or IL-6. Journal of the American Society of Nephrology: JASN, 2007, 18, 1167-1179.	6.1	70

#	Article	IF	Citations
73	Peritonitis, peritoneal inflammation and membrane permeability: a longitudinal study of dialysate and serum MCP-1 in stable patients on peritoneal dialysis. Journal of Nephrology, 2007, 20, 340-9.	2.0	8
74	Increased expression of the pro-apoptotic ATP-sensitive P2X7 receptor in experimental and human glomerulonephritis. Nephrology Dialysis Transplantation, 2006, 22, 386-395.	0.7	73
75	Current pharmacotherapy for the treatment of crescentic glomerulonephritis. Expert Opinion on Investigational Drugs, 2006, 15, 1353-1369.	4.1	11
76	Antibody blockade of TNF-Î± reduces inflammation and scarring in experimental crescentic glomerulonephritis. Kidney International, 2005, 67, 1812-1820.	5.2	128
77	Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitis. Nephrology Dialysis Transplantation, 2004, 19, 2761-2768.	0.7	94
78	Fragmentation of filtered proteins and implications for glomerular protein sieving in Fanconi syndrome. Kidney International, 2002, 62, 349.	5.2	4
79	Glomerular protein sieving and implications for renal failure in Fanconi syndrome. Kidney International, 2001, 60, 1885-1892.	5.2	207
80	Interleukin-11 Attenuates Nephrotoxic Nephritis in Wistar Kyoto Rats. Journal of the American Society of Nephrology: JASN, 2001, 12, 2310-2320.	6.1	28
81	CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis. Journal of Clinical Investigation, 2000, 105, 643-651.	8.2	158
82	Interleukin-4 ameliorates crescentic glomerulonephritis in Wistar Kyoto rats. Kidney International, 1999, 55, 1319-1326.	5.2	45
83	Arginase AI Is Upregulated in Acute Immune Complex-Induced Inflammation. Biochemical and Biophysical Research Communications, 1998, 247, 84-87.	2.1	39
84	Arginase activity is modulated by IL-4 and HOArg in nephritic glomeruli and mesangial cells. American Journal of Physiology - Renal Physiology, 1998, 274, F473-F480.	2.7	21
85	Interleukin-4 ameliorates experimental glomerulonephritis and up-regulates glomerular gene expression of IL-1 decoy receptor. Kidney International, 1997, 52, 1224-1231.	5.2	38
86	Abrogation of glomerular injury in nephrotoxic nephritis by continuous infusion of interleukin-6. Kidney International, 1997, 52, 1313-1320.	5.2	39
87	Differential expression of macrophage inflammatory protein-2 and monocyte chemoattractant protein-1 in experimental glomerulonephritis. Kidney International, 1996, 49, 715-721.	5.2	44
88	UP-REGULATION OF TYPE 1 PLASMINOGEN ACTIVATOR INHIBITOR MESSENGER RNA WITH THROMBOTIC CHANGES IN RENAL GRAFTS1. Transplantation, 1996, 61, 684-689.	1.0	12
89	Modulation of antibody-mediated glomerular injury in vivo by IL-1ra, soluble IL-1 receptor, and soluble TNF receptor. Kidney International, 1995, 48, 1738-1746.	5.2	58
90	Modulation of antibody-mediated glomerular injury in vivo by interleukin-6. Kidney International, 1993, 44, 967-973.	5.2	29

#	Article	IF	Citations
91	The Role of Continuous Ambulatory Peritoneal Dialysis in End-Stage Renal Failure Due to Multiple Myeloma. American Journal of Kidney Diseases, 1990, 16, 216-223.	1.9	34
92	Aversive effects of subcutaneously injected vasopressin in the rat: independence of the ascending dorsal noradrenergic bundle. Brain Research, 1985, 337, 133-137.	2.2	4